Culture

Factors associated with US public motivation to use, distribute COVID-19 self-tests

What The Study Did: Researchers examined individuals' motivation to self-test and to distribute self-test kits given the urgent need to increase COVID-19 testing coverage and contact tracing.

Author: Cedric Bien-Gund, M.D., of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2020.34001)

Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2020.34001?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=012021

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Credit: 
JAMA Network

Association of social, economic inequality with COVID-19 across US counties

What The Study Did: This investigation analyzed U.S. county-level associations of income inequality, racial/ethnic composition and political attributes with COVID-19 cases and mortality.

Author: Tim F. Liao, Ph.D., of the University of Illinois at Urbana-Champaign, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2020.34578)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2020.34578?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=012021

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Credit: 
JAMA Network

Automated imaging reveals where TAU protein originates in the brain in Alzheimer's disease

image: Four views of the origin of tauopathy in vivo. Left, TAU PET images for a cognitively normal person; right: top, 3D rendering of brain surface with TAU PET overlay; bottom, flat map showing topographic detail of surface anatomy with TAU origin identified in white outline. This material relates to a paper that appeared in the Jan. 20, 2021, issue of Science Translational Medicine, published by AAAS. The paper, by J.S. Sanchez at Massachusetts General Hospital in Boston, MA; and colleagues was titled, "The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography."

Image: 
[Justin Sanchez and Keith Johnson, Massachusetts General Hospital]

Researchers have developed an automated method that can track the development of harmful clumps of TAU protein related to Alzheimer's disease in the brain, according to work involving 443 individuals. The method revealed that TAU primarily emerged in an area of the brain called the rhinal cortex before spreading elsewhere, suggesting that targeting TAU here could potentially slow the progression of Alzheimer's disease. The buildup of toxic amyloid-beta and TAU proteins is responsible for many of the symptoms and damage to neurons seen in Alzheimer's disease. However, current therapies have shown reduced efficacy, at least in part because the therapies were administered long after the protein had spread throughout the brain. Developing more effective interventions therefore requires a better understanding of where TAU pathology originates and how it spreads. Justin Sanchez and colleagues designed an automated anatomic sampling method that uses PET imaging to track the presence of TAU in the brain. The team applied their technique to 443 adult participants - including 55 patients with Alzheimer's - and discovered that TAU deposits first emerged in the rhinal cortex independently from amyloid-beta before spreading to the temporal neocortex. A two-year experiment with 104 subjects showed that people with the highest initial levels of TAU or amyloid beta displayed the most spread of TAU throughout the brain by the end of the study. "These findings suggest that [the rhinal cortex] is a biomarker of downstream TAU spread ... with potential utility for therapeutic trials in which reduction of TAU spread is an outcome measure," the authors conclude.

Credit: 
American Association for the Advancement of Science (AAAS)

Deep sleep takes out the trash

image: Proboscis fully extends (red arrow) and then immediately retracts during proboscis extension sleep, which is similar to slow-wave sleep in humans.

Image: 
Ravi Allada/Northwestern University

A new Northwestern University study reaffirms the importance of getting a good night's sleep.

By examining fruit flies' brain activity and behavior, the researchers found that deep sleep has an ancient, restorative power to clear waste from the brain. This waste potentially includes toxic proteins that may lead to neurodegenerative disease.

"Waste clearance could be important, in general, for maintaining brain health or for preventing neurogenerative disease," said Dr. Ravi Allada, senior author of the study. "Waste clearance may occur during wake and sleep but is substantially enhanced during deep sleep."

The study will publish tomorrow (Jan. 20) in the journal Science Advances.

Allada is the Edward C. Stuntz Distinguished Professor in Neuroscience and chair of the Department of Neurobiology in the Northwestern's Weinberg College of Arts and Sciences. He also is associate director of Northwestern's Center for Sleep and Circadian Biology. Bart van Alphen, a postdoctoral fellow in Allada's laboratory, was the paper's first author.

Although fruit flies seem very different from humans, the neurons that govern flies' sleep-wake cycles are strikingly similar to our own. For this reason, fruit flies have become a well-studied model organism for sleep, circadian rhythms and neurodegenerative diseases.

In the current study, Allada and his team examined proboscis extension sleep (PES), a deep-sleep stage in fruit flies, which is similar to deep, slow-wave sleep in humans. The researchers discovered that, during this stage, fruit flies repeatedly extend and retract their proboscis (or snout).

"This pumping motion moves fluids possibly to the fly version of the kidneys," Allada said. "Our study shows that this facilitates waste clearance and aids in injury recovery."

When Allada's team impaired flies' deep sleep, the flies were less able to clear an injected non-metabolizable dye from their systems and were more susceptible to traumatic injuries.

Allada said this study brings us closer to understanding the mystery of why all organisms need sleep. All animals -- especially those in the wild -- are incredibly vulnerable when they sleep. But research increasingly shows that the benefits of sleep -- including crucial waste removal -- outweigh this increased vulnerability.

"Our finding that deep sleep serves a role in waste clearance in the fruit fly indicates that waste clearance is an evolutionary conserved core function of sleep," the paper's coauthors write. "This suggests that waste clearance may have been a function of sleep in the common ancestor of flies and humans."

Credit: 
Northwestern University

Intoxicating chemicals in catnip and silver vine protect felines from mosquito bites

Rubbing against catnip and silver vine transfers plant chemicals that researchers have now shown protect cats from mosquitoes. The results also demonstrate that engaging with nepetalactol, which the study identified as the most potent of many intoxicating iridoid compounds found in silver vine, activates the opioid reward system in both domesticated felines and big jungle cats. While nepetalactol had been previously identified, these studies directly illuminate its extremely potent effect on cats. And by revealing the biological significance of well-known feline behaviors, the study opens the door to further inquiry into how nepetalactol's twin effects - pest repellence and intoxication - may have driven the evolution of these behaviors. Catnip and silver vine are known to hold a special place in felines' hearts. When cats encounter these plants, they rub their heads and faces against them and roll around on the ground, displaying undeniable enjoyment. Afterward, the cats lounge around in a state of intoxicated repose. But while pet owners around the world gift their cats toys laced with catnip or silver vine leaves, the biological significance of these plants and the neurophysiological mechanism triggered when cats sniff and rub against them has not been known. To investigate, Reiko Uenoyama and colleagues tested how 25 laboratory cats, 30 feral cats, and several captive big cats, including an Amur leopard, two jaguars, and two Eurasian lynx, responded to filter paper impregnated with nepetalactol, finding that the cats showed a more prolonged response than they did with untreated control filter papers. In contrast, dogs and laboratory mice showed no interest in the nepetalactol-containing papers. Next, the researchers compared how 12 of the cats responded to each of the known bioactive iridoids, finding that nepetalactol is the most potent compound in silver vine leaves. To test whether feline responses to nepetalactol are regulated by the opioid system, they examined changes in plasma levels of ?-endorphin 5 minutes before and 5 minutes after 5 cats were exposed to nepetalactol, and later to a control stimulus, finding elevated endorphin concentrations only after exposure to the iridoid. When the researchers pharmacologically inhibited the cats' ?-opioid receptors, the cats no longer showed a rubbing response to the iridoid. Finally, they tested whether silver vine leaves repelled Aedes albopictus mosquitoes when cats rubbed against the plant, finding that significantly fewer mosquitoes landed on cats that exhibited this behavior. Uenoyama et al. note that nepetalactol might also be used as a repellent to protect humans from mosquitoes and suggest it could also repel the Aedes aegypti species, which transmits yellow fever, dengue, and Zika viruses.

Credit: 
American Association for the Advancement of Science (AAAS)

Designer DNA therapeutic wipes out cancer stem cells, treats multiple myeloma in mice

image: The left image represents a microscopic view of the bone marrow of a myeloma-bearing mouse treated with control, and the right image represents the same for a myeloma-bearing mouse treated with the antisense oligonucleotide ION251, an experimental therapeutic. The red dots represent the IRF4 protein within human myeloma cells, which are much sparser after ION251 treatment.

Image: 
UC San Diego Health Sciences

Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.

Researchers at University of California San Diego School of Medicine and Ionis Pharmaceuticals are taking a new, targeted approach to myeloma treatment -- silencing IRF4, a gene that allows myeloma stem cells and tumor cells to proliferate and survive. Past studies have shown that high IRF4 levels are associated with lower overall survival rates for patients with the disease.

In a study published January 20, 2021 in Cell Stem Cell, the team details their successes inhibiting IRF4 with an antisense oligonucleotide, an engineered piece of DNA specifically designed to bind the genetic material coding for IRF4, causing it to degrade. The oligonucleotide -- an investigational antisense medicine developed by Ionis and known as ION251 -- lowered disease burden, reduced myeloma stem cell abundance and increased survival of mice bearing human myeloma, according to preclinical study data.

Authors say the results support a Phase I clinical trial recently launched to assess the safety and efficacy of ION251 to treat humans with myeloma.

"As scientists, we don't usually have direct contact with patients, as a daily reminder of what our research could do, or why it's important," said co-senior author Leslie Crews, PhD, assistant professor in the Division of Regenerative Medicine at UC San Diego School of Medicine. "But I've been working with a local support group for patients with multiple myeloma. They inspire me. They ask the most insightful questions, and it really makes it personal. I hope this work will eventually give them new potential treatments to prevent relapse, and ultimately get better."

UC San Diego School of Medicine and Ionis Pharmaceuticals have a long history of collaborating on the development of investigational antisense medicines. Several Ionis antisense drugs have been commercially approved, including the U.S. Food and Drug Administration (FDA)-approved SPINRAZA, a therapy for spinal muscular atrophy. In addition, several other therapies are currently in clinical trials.

One challenge myeloma researchers face is that myeloma cells don't grow well in laboratory dishes. To study the disease and test new treatments, the best method, Crews said, is to transplant human myeloma cells into mice that lack an immune system and thus won't reject the human cells -- making avatars of each unique patient, in a way.

The team tested ION251 on these myeloma mouse avatars. Compared to untreated mice, the treated mice had significantly fewer myeloma cells after two to six weeks of treatment. What's more, 70 to 100 percent of the treated mice survived, whereas none of the untreated control mice did. There were 10 mice in each treatment or control group and they received daily doses of ION251 or a control for one week, followed by three doses per week.

In separate experiments using human cells isolated from myeloma or healthy donor samples, doses of ION251 used were enough to eradicate the myeloma stem cells while sparing healthy blood cells.

"The results of these preclinical studies were so striking that half the microscopy images we took to compare bone marrow samples between treated and untreated mice kept coming back blank -- in the treated mice, we couldn't find any myeloma cells left for us to study," said Crews, who is also associate member of the Moores Cancer Center and member of the Altman Clinical and Translational Research Institute at UC San Diego. "It makes the science more difficult, but it gives me hope for patients."

In addition to working on its own, the treatment improved myeloma tumor cell sensitivity to standard-of-care cancer therapeutics. The researchers also drilled down to the mechanisms at play and described the molecular effects of IRF4 inhibition -- information that both clarifies how myeloma forms in the first place, and how the treatment works.

"These proof-of-principle studies will enable rapid clinical development of anti-sense oligonucleotide-mediated IRF4 inhibition to prevent myeloma relapse driven by drug-resistant cancer stem cells," said co-senior author Catriona Jamieson, MD, PhD, Koman Family Presidential Endowed Chair in Cancer Research, deputy director of Moores Cancer Center, director of the Sanford Stem Cell Clinical Center and director of the CIRM Alpha Stem Cell Clinic at UC San Diego Health.

The Phase I clinical trial to assess the safety of ION251, sponsored by Ionis Pharmaceuticals, is now recruiting participants at Moores Cancer Center at UC San Diego Health and elsewhere. More information is available at clinicaltrials.gov/ct2/show/NCT04398485.

"This collaboration exemplifies the power of combining Ionis' antisense technology to target previously un-druggable factors in cancer, with world-class academic, translational and clinical research from institutions such as UC San Diego to rapidly bring promising drugs to patients desperately in need," said co-senior author A. Robert MacLeod, PhD, vice president and franchise head of Oncology at Ionis Pharmaceuticals.

According to the National Cancer Institute, multiple myeloma is the second most common blood cancer in the United States, with more than 32,000 new cases predicted in 2020 and a five-year survival of only 53.9 percent.

Credit: 
University of California - San Diego

Eye tests predict Parkinson's-linked cognitive decline 18 months ahead

Simple vision tests can predict which people with Parkinson's disease will develop cognitive impairment and possible dementia 18 months later, according to a new study by UCL researchers.

The study, published in Movement Disorders, adds to evidence that vision changes precede the cognitive decline that occurs in many, but not all, people with Parkinson's.

In another new study published today in Communications Biology, the same research team found that structural and functional connections of brain regions become decoupled throughout the entire brain in people with Parkinson's disease, particularly among people with vision problems.

The two studies together show how losses and changes to the brain's wiring underlie the cognitive impairment experienced by many people with Parkinson's disease.

Lead author Dr Angeliki Zarkali (Dementia Research Centre, UCL Queen Square Institute of Neurology) said: "We have found that people with Parkinson's disease who have visual problems are more likely to get dementia, and that appears to be explained by underlying changes to their brain wiring.

"Vision tests might provide us with a window of opportunity to predict Parkinson's dementia before it begins, which may help us find ways to stop the cognitive decline before it's too late."

For the Movement Disorders paper, published earlier this month, the researchers studied 77 people with Parkinson's disease and found that simple vision tests predicted who would go on to get dementia after a year and a half.

Dementia is a common, debilitating aspect of Parkinson's disease, estimated to affect roughly 50% of people within 10 years of a Parkinson's diagnosis.

These longitudinal findings add weight to previous studies that were done at one time point, which had suggested that performance in vision tests, involving commonly used eye charts and skewed images of cats and dogs, was linked to the risk of cognitive decline.

The new study also found that those who went on to develop Parkinson's dementia had losses in the wiring of the brain, including in areas relating to vision and memory. The researchers used recently developed methods to analyse finely detailed MRI scans, enabling them to pick up the damage to the brain's white matter.

The researchers identified white matter damage to some of the long-distance wiring connecting the front and back of the brain, which helps the brain to function as a cohesive whole network.

The Communications Biology study involved 88 people with Parkinson's disease (33 of whom had visual dysfunction and were thus judged to have a high risk of dementia) and 30 healthy adults as a control group, whose brains were imaged using MRI scans.

In the healthy brain, there is a correlation between how strong the structural (physical) connections between two regions are, and how much those two regions are connected functionally. That coupling is not uniform across the brain, as there is some degree of decoupling in the healthy brain, particularly in areas involved in higher-order processing, which might provide the flexibility to enable abstract reasoning. Too much decoupling appears to be linked to poor outcomes.

The researchers found that people with Parkinson's disease exhibited a higher degree of decoupling across the whole brain. Areas at the back of the brain, and less specialised areas, had the most decoupling in Parkinson's patients.

Parkinson's patients with visual dysfunction had more decoupling in some, but not all brain regions, particularly in memory-related regions in the temporal lobe.

The research team also found changes to the levels of some neurotransmitters (chemical messengers) in people at risk of cognitive decline, suggesting that receptors for those transmitters may be potential targets for new drug treatments for Parkinson's dementia. Notably, while dopamine is known to be implicated in Parkinson's, the researchers found that other neurotransmitters - acetylcholine, serotonin and noradrenaline - were particularly affected in people at risk of cognitive decline.

Dr Angeliki said: "The two papers together help us to understand what's going on in the brains of people with Parkinson's who experience cognitive decline, as it appears to be driven by a breakdown in the wiring that connects different brain regions."

Dr Rimona Weil (UCL Queen Square Institute of Neurology), senior author of both papers, said: "Our findings could be valuable for clinical trials, by showing that vision tests can help us identify who we should be targeting for trials of new drugs that might be able to slow Parkinson's. And ultimately if effective treatments are found, then these simple tests may help us identify who will benefit from which treatments."

Credit: 
University College London

Dinosaur-era sea lizard had teeth like a shark

image: Xenodens calminechari was about the size of a small porpoise and had serrated shark-like teeth.

Image: 
Andrey Atuchin

New study identifies a bizarre new species suggesting that giant marine lizards thrived before the asteroid wiped them out 66 million years ago.

A new species of mosasaur - an ancient sea-going lizard from the age of dinosaurs - has been found with shark-like teeth that gave it a deadly slicing bite.

Xenodens calminechari, from the Cretaceous of Morocco, had knifelike teeth that were packed edge to edge to make a serrated blade and resemble those of certain sharks. The cutting teeth let the small, agile mosasaur, about the size of a small porpoise, punch above its weight, cutting fish in half and taking large bites from bigger animals.

Dr Nick Longrich, Senior Lecturer at the Milner Centre for Evolution at the University of Bath and lead author on the paper, said: "66 million years ago, the coasts of Africa were the most dangerous seas in the world.

"Predator diversity there was unlike anything seen anywhere else on the planet. The new mosasaur adds to a rapidly growing list of marine reptiles known from the latest Cretaceous of Morocco, which at the time was submerged beneath a tropical sea.

"A huge diversity of mosasaurs lived here. Some were giant, deep-diving predators like modern sperm whales, others with huge teeth and growing up to ten meters long, were top predators like orcas, still others ate shellfish like modern sea otters - and then there was the strange little Xenodens.

"They coexisted with long-necked plesiosaurs, giant sea turtles, and saber-toothed fish. The new mosasaur adds another dangerous predator to the mix."

The discovery also adds to the diversity of marine reptiles in the late Cretaceous. This suggests their diversity peaked just before an asteroid hit 66 million years ago, wiping out marine reptiles and the dinosaurs.

"We're still learning how diverse the mosasaurs were," said Longrich. "And whenever we think we have them figured out, another one turns up."

The fauna lived in the million years before an asteroid hit the earth at the end of the Cretaceous period, ending the reign of the dinosaurs and wiping out 90 per cent or more of all species on Earth. The high diversity found in the new study suggests that the ecosystem wasn't in decline before the asteroid hit; instead the ecosystem seems to suggest that marine reptiles were expanding in diversity before they abruptly went extinct.

The teeth seen in Xenodens are unlike those of any other reptile. But Dr Longrich, who worked on fishing boats growing up in Alaska, had seen something similar before.

He said: "It reminded me of the teeth in the jaws of the sleeper sharks we'd sometimes catch while fishing halibut on my brother's boat. I remember seeing what those sharks could do- they'd carve huge bolts of flesh out of the halibut, almost cutting them in half."

The authors suggest that, similar to sleeper sharks and related dogfish sharks, the unusual jaws allowed the animal to punch above its weight, cutting small fish in half, carving pieces out of larger prey, and perhaps even scavenging on the carcasses of large marine reptiles.

But rather than being an extreme specialist, the teeth probably let Xenodens eat a huge range of prey - "They're like the knives sold on those old late night TV commercial- they'll slice through anything," said Longrich.

Anne Schulp, researcher at Naturalis Biodiversity Center in Leiden and Professor of Palaeontology at Utrecht University, and an author on the paper, said: "I'm blown away by the new discovery.

"I've been working on closely related mosasaurs for a decade or two now, and Xenodens shows this group managed to exploit yet another food source. They clearly were even more successful than we thought."

Dr Nathalie Bardet from the National Museum of Natural History in Paris said: "I have been working on mosasaurs for over 20 years and more specifically on those from the Maastrichtian Phosphates of Morocco which I am familiar with. I must admit that among the ten species that I know, this one has a so unusual and extraordinary dentition that at the beginning I thought it was a 'chimera' reconstructed with different fossils!"

Dr Nour-Eddine Jalil of the National Museum of Natural History in Paris and Universite Cadi Ayyad in Marrakech, said: "A mosasaur with shark teeth is a novel adaptation of mosasaurs so surprising that it looked like a fantastic creature out of an artist's imagination.

"Xenodens calminechari is further evidence of the extraordinary paleobiodiversity of the Phosphate Sea.

"It is as if nature is struggling to find all the combinations for an ever finer exploitation of food sources."

Credit: 
University of Bath

Clumsy kids can be fit too

image: The study clearly demonstrates that aerobic fitness is not linked to motor skills.

Image: 
Photo: University of Jyväskylä

Clumsy kids can be as aerobically fit as their peers with better motor skills, a new Finnish study shows. The results are based on research conducted at the Faculty of Sport and Health Sciences of the University of Jyväskylä and the Institute of Biomedicine of the University of Eastern Finland, and they were published in Translational Sports Medicine.

Aerobic fitness doesn't go hand in hand with motor skills

According to the general perception, fit kids also have good motor skills, while low aerobic fitness has been thought to be a link between poor motor skills and overweight. This perception is based on studies whose methods do not distinguish between the roles of aerobic fitness and body fat content as risk factors for poor motor skills and overweight.

"Our study clearly demonstrated that aerobic fitness is not linked to motor skills when body composition is properly taken into account," explains Eero Haapala, Ph.D., from the Faculty of Sport and Health Sciences at the University of Jyväskylä.

"Also, aerobic fitness was not strongly associated with overweight or obesity. Therefore, it seems that the role of poor aerobic fitness as a risk factor for poor motor skills and excess body weight has been strongly exaggerated."

The development of motor skills can be supported

This study did not look at the role of exercise in the development of motor skills, but earlier studies have shown that a range of exercise, varying in motor challenges and intensity, contributes to the development of motor skills, regardless of aerobic fitness and body fat content. Higher levels of physical activity and less sedentary behaviour can also protect against the development of excess weight.

"The key message of our study is that even a child who is unfit can be motorically adept and the heart of a clumsier kid can be as fit as her or his more skilful peer," Haapala says. "In addition, high levels of varied physical activity and reduced sedentary behaviour are central to the development of motor skills and the prevention of excess weight gain since childhood."

The study investigated the associations between aerobic fitness, body fat content, and motor skills in 332 children aged 7 to 11 years. Aerobic fitness was measured by maximum bicycle ergometer test and body composition with bioimpedance and DXA devices. Motor skills were measured by common methods.

Credit: 
University of Jyväskylä - Jyväskylän yliopisto

TGen-NAU study: COVID-19 virus triggers antibodies from previous coronavirus infections

FLAGSTAFF, Ariz. -- Jan. 19, 2021 -- The results of a study led by Northern Arizona University and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest the immune systems of people infected with COVID-19 may rely on antibodies created during infections from earlier coronaviruses to help fight the disease.

COVID-19 isn't humanity's first encounter with a coronavirus, so named because of the corona, or crown-like, protein spikes on their surface. Before SARS-CoV-2 -- the virus that causes COVID-19 -- humans have navigated at least 6 other types of coronaviruses.

The study sought to understand how coronaviruses (CoVs) ignite the human immune system and conduct a deeper dive on the inner workings of the antibody response. The published findings appear today in the journal Cell Reports Medicine.

"Our results suggest that the COVID-19 virus may awaken an antibody response that existed in humans prior to our current pandemic, meaning that we might already have some degree of pre-existing immunity to this virus." said John Altin, Ph.D., an Assistant Professor in TGen's infectious disease branch and the study's senior author.

This knowledge could help researchers design new diagnostics, evaluate the healing powers of convalescent plasma, develop new therapeutic treatments, and -- importantly -- help design future vaccines or monoclonal antibody therapies capable of protecting against mutations that may occur in the COVID-19 virus.

The researchers used a tool called PepSeq to finely map antibody responses to all human-infecting coronaviruses. PepSeq is a novel technology being developed at TGen and NAU that allows for the construction of highly diverse pools of peptides (short chains of amino acids) bound to DNA tags. When combined with high-throughput sequencing, these PepSeq molecule pools allow for deep interrogation of the antibody response to viruses.

"The data generated using PepSeq allowed for broad characterization of the antibody response in individuals recently infected with SARS-CoV-2 compared with those of individuals exposed only to previous coronaviruses that now are widespread in human populations," said Jason Ladner, Ph.D., an Assistant Professor at NAU's Pathogen and Microbiome Institute, which combines the academic genomic research focus of NAU and the translational genomics capacity of TGen. Dr. Ladner is the study's lead author.

Besides SARS-CoV-2, researchers examined the antibody responses from two other potentially deadly coronaviruses: MERS-CoV, which caused the 2012 outbreak in Saudi Arabia of Middle East Respiratory Syndrome; and SARS-CoV-1, the first pandemic coronavirus that caused the 2003 outbreak in Asia of Severe Acute Respiratory Syndrome. All three are examples of coronaviruses that infect animals, but evolved to make people sick and became new human pathogens.

In addition to characterizing antibodies that recognize SARS-CoV-2, they also examined the antibody responses of four older coronaviruses: alphacoronavirus 229E; alphacoronavirus NL63; betacoronavirus OC43; and betacoronavirus HKU1. These so called "common" coronaviruses are endemic throughout human populations, but usually are not deadly and cause mild upper respiratory infections similar to those of the common cold.

By comparing patterns of reactivity against these different coronaviruses, the researchers demonstrated that SARS-CoV-2 could summon immune system antibodies originally generated in response to past coronavirus infections. This cross-reactivity occurred at two sites in the SARS-CoV-2 Spike protein; the protein on the surface of virus particles that attaches to ACE2 proteins on human cells to facilitate cell entry and infection.

"Our findings highlight sites at which the SARS-CoV-2 response appears to be shaped by previous coronavirus exposures, and which have potential to raise broadly-neutralizing antibodies. We further demonstrate that these cross-reactive antibodies preferentially bind to endemic coronavirus peptides, suggesting that the response to SARS-CoV-2 at these regions may be constrained by previous coronavirus exposure," said Dr. Altin, adding that more research is needed to understand the implications of these findings.

The findings could help explain the widely varying reactions COVID-19 patients have to the disease; from mild to no symptoms, to severe infections requiring hospitalization, and often resulting in death. It's also possible that differences in the pre-existing antibody response identified by this study could help to explain some of the difference in how severely COVID-19 disease manifests in old versus young people, who will have different histories of infections with the common coronaviruses.

"Our findings raise the possibility that the nature of an individual's antibody response to prior endemic coronavirus infection may impact the course of COVID-19 disease," Dr. Ladner said.

Credit: 
The Translational Genomics Research Institute

Different types of neurons interact to make reaching-and-grasping tasks possible

video: Inhibiting or exciting D1 or D2 neurons has different impacts on the mouse. The first clip shows a mouse with both D1 and D2 neurons working as normal successfully retrieving the reward. The second clip shows a mouse whose D1 neurons have been excited failing to retrieve the reward due to an initial error. The third clip shows a mouse whose D2 neurons have been excited failing to retrieve the reward due to a final error.

Image: 
The video clips were published in the research paper in Cell Reports.

Researchers looked at neurons within the basal ganglia, a part of the brain that, when damaged, can severely impact a person's motor ability, making seemingly simple reaching-and-grasping tasks near impossible

They focused on a large group of neurons, which has two distinct types - D1 direct striatal output neurons and D2 indirect output neurons

These neurons are implicated in the development of Parkinson's and Huntington's - neurodegenerative diseases that result in the progressive degeneration or death of nerve cells

In this research, mice were trained to reach for and grasp a chocolate pellet, and optical methods were used to either excite or inhibit their D1 or D2 neurons

The researchers found that both types of neurons were necessary for performing the task, with D1 neurons providing the early part of the movement and D2 neurons providing the final approach to the target

Research conducted at the Okinawa Institute of Science and Technology Graduate University (OIST), has looked at the importance of specific neurons for seemingly simple, day-to-day tasks that involve reaching for and grasping objects. The study was published in Cell Reports.

"We focused on the neurons located in the basal ganglia," said Professor Gordon Arbuthnott, who leads OIST's Brain Mechanisms for Behavior Unit. "This part of the brain is connected to the cerebral cortex, which is involved in motor function. And neurons, or nerve cells, are specialized cells that act as the building blocks of the nervous system - they connect input from the outside world to movement in our muscles."

Patients that suffer from damage to the basal ganglia can have their motor abilities severely impacted, making daily reaching-and-grasping tasks, like picking up a cup of coffee or putting on a jacket, near impossible.

"We know that interruptions to these basal ganglia neurons are involved in the development of diseases like Parkinson's and Huntington's, but the exact cellular mechanisms behind this isn't properly understood," Professor Arbuthnott went on to explain.

The neurons in question are striatal spiny projection neurons, a large group that contributes to smooth motor function. There are two distinct types - D1 direct striatal output neurons, which connect directly with the output of the basal ganglia, and D2 indirect output neurons, which take a longer route via other areas of the brain. Depending on a person's behavior, different groups made up of different compositions of these two neurons will form. Most groups have both D1 and D2 neurons although there are exceptions, with some groups only having one. Thus, it's a dynamic system where the two different types work together. Previous research has indicated that, for tasks involving movement, the D1 neurons give the 'go' signal whereas the D2 neurons give the 'stop' signal. The researchers decided to change the activity of each type independently, to test this idea.

To perform the experiment, mice were trained to reach through an opening in their chamber and grasp a chocolate food pellet. Failure to retrieve the pellet was classed in one of three ways. An 'initial' error occurred when the mouse couldn't get their paw through the opening of their chamber. A 'final' error was when a mouse's paw ended in the wrong place after it crossed the opening. And a 'grasp' error was when the mouse's paw made it to the pellet, but they were unable to pick it up.

When mice with both D1 and D2 neurons working as normal were trained in this task, they were most likely to fail with the grasp error, which occurred in more than half the failures. With this in mind, the researchers used optical methods so that either D1 neurons or D2 neurons could be excited or inhibited by light.

The researchers found that both exciting and inhibiting the D1 type resulted in a significant decrease in the success rate of treat retrieval, and that, proportionately, the number of failures from the 'initial' error increased.

In contrast, exciting the D2 type also resulted in a significant decrease in the success rate but, this time, it was the 'final' error that increased proportionately.

But, interestingly, when the D2 types were inhibited, the success rate of treat retrieval increased.

"We have several ideas as to why this might have occurred," said Professor Arbuthnott. "If we imagine that a small group of D2 neurons is enough to reach the target then exciting all the D2 cells in the area might make the small group get lost in the noisy activity of the many, while inhibiting the large group could leave behind just the most strongly excited neurons, which can then effectively guide the mouse's behavior."

The results found that both types were necessary for the smooth motor function of all movement. The mice have trouble with the starting part of the movement without the D1 cells; and, in most cases, the pellet cannot be retrieved if the D2 cells aren't working correctly. However, the stop-and-go theory was not supported by this study as, although D1 cells were found to be necessary for controlling the initial part of the reach, the researchers found that D2 cells were actually needed for aiming for the treat, rather than stopping the task.

"This study has helped us understand more about how our brains work and contributes to the body of research that will one day make finding a cure to neurodegenerative diseases possible," said Professor Arbuthnott. "With Parkinson's disease, we're getting good at fixing the symptoms, but we need to get to the root of the disease. In the meantime, understanding how neurons are involved in movement control will help to solve the problems facing patients on a daily basis."

Credit: 
Okinawa Institute of Science and Technology (OIST) Graduate University

Scientists present novel approach for monitoring freshwater health

image: The MinION is a portable device that can sequence genetic material sampled from the environment - here, from the River Cam in Cambridge, UK.

Image: 
Team PuntSeq (CC BY 4.0)

Researchers have used the world's smallest, smartphone-sized DNA sequencing device to monitor hundreds of different bacteria in a river ecosystem.

Writing in the journal eLife, the interdisciplinary team from the University of Cambridge, UK, provide practical and analytical guidelines for using the device, called the MinION (from Oxford Nanopore Technologies), to monitor freshwater health. Their guidelines promise a significantly more cost-effective and simple approach to this work outside the lab, compared to existing methods.

Rowers and swimmers in Cambridge are regularly affected by waterborne infections such as Weil's disease, sometimes leading to public closures of the city's iconic waterways. Monitoring the microbial species in freshwater can help indicate the presence of disease-causing microorganisms and even water pollution. But traditional tests for freshwater bacteria often require well-equipped laboratories and complex methods for growing colonies of individual bacterial species.

"The direct measurement of all bacterial DNA traces in freshwater, an approach known as metagenomics, is a valuable alternative, but still requires large, expensive equipment that can be hard to operate," says Andre Holzer, co-first author and PhD student at the Department of Plant Sciences, University of Cambridge. "We aimed to describe the bacterial species present in the River Cam using the new portable DNA sequencing technology."

The team used the MinION device to sequence the DNA of entire groups of microorganisms found in water samples from the River Cam. But before they could use the sequence data, they needed to optimise their experimental methods and analysis software. "It was essential to account for the quality of this new type of bacterial DNA sequence information," Holzer explains. "We tested many different algorithms for processing the data to find the most accurate methods."

The researchers then used their optimised guidelines to analyse the data and successfully measure the proportions of hundreds of different bacterial species present in the water. They took samples from nine different sites along the river, often sampling the sites at three different time points so they could compare the proportions of species in different locations and seasons.

The team was also able to distinguish closely related, harmful microbial species from non-harmful ones. By comparing the samples from different locations, they found that there were more potentially harmful bacteria and those associated with wastewater downstream of the most built-up, urban areas of the river. Chemical follow-up analyses of the water samples collected from the same urban areas revealed a matching trend of increasing wastewater pollution in those areas.

"Our work shows how MinION and the associated DNA sequencing technology can be used in the effective monitoring of freshwater health," says Lara Urban, co-lead investigator of the work and now an Alexander von Humboldt Research Fellow at the University of Otago, New Zealand. "This expands on the technology's existing applications which include the accurate tracing of viral transmissions between patients during the recent Ebola, Zika and SARS-CoV-19 virus outbreaks."

"We hope our results will encourage other independent scientists and collectives to engage in simplified freshwater management and biodiversity tests around the globe,"concludes senior author Maximilian Stammnitz, a PhD student at the Department of Veterinary Medicine, University of Cambridge.

Credit: 
eLife

New negative pressure ventilator requiring fewer staffing resources developed in fight against COVID-19

A new negative pressure ventilator which could provide additional treatment options for patients with respiratory failure, including those with COVID-19 - and whose design can be easily adapted to developing countries - has been created by a team that includes anaesthetists, nurses and engineers. Details on the new exovent system - which is similar in design but much smaller in scale and easier to use than the devices used to help treat polio patients during the 1950s - are published in Anaesthesia (a journal of the Association of Anaesthetists).

Use of this system would offer more comfort to patients, who would not need to be asleep or have an artificial airway in place, although the authors make it clear that a clinical trial is required to fully test it. After monitoring patients closely at first, the system would also mean less nursing care and could be used anywhere in the hospital, and even potentially at home. Staffing requirements for the new system would be typically much lower than for today's typical intensive care unit ventilators, and lower than other non-intensive positive pressure systems for the equivalent severity of illness.

Negative pressure devices lower the pressure outside the body to allow lung tissue to expand and function in a way that is like normal breathing, while positive pressure devices such as the conventional ventilators and continuous positive airway pressure (CPAP) systems in current use push air into the lungs under positive pressure. Research into negative pressure devices had been mostly abandoned since the 1950s, since positive pressure devices had become much smaller, cheaper and more convenient.

The exovent task force formed in March 2020 in response to the COVID-19 crisis, inspired by calls from the UK Government for rapid innovation to combat the challenge presented by SARS-CoV-2. The team is composed of anaesthetists, critical care consultants, nurses, medical clinicians, engineers, academics, scientists and manufacturers. This initiative was not part of the UK's 'Ventilator Challenge', because that project encouraged innovation for positive pressure devices only.

"The exovent team focused on exploring the benefits of negative pressure ventilation, founded upon lessons learned from nearly 100 years of using negative pressure ventilation, most memorably during the polio epidemic of the 1950s," explains co-author Dr Malcolm Coulthard of the Translational and Clinical Research Institute, Newcastle University, UK.

Use of negative pressure is far less intrusive and much more like normal breathing than either positive pressure ventilation through a tube inserted into the windpipe, or delivering CPAP via a tightly-fitting face mask. The exovent system is non-invasive, which means that patients do not need to have their windpipes intubated, so they don't need to be anaesthetised and oxygen can be delivered in the form of a normal oxygen mask or nasal prongs rather than through a high flow oxygen device that puts hospital oxygen supplies under pressure. Patients remain conscious, and can take food and medication by mouth, and talk to loved ones on the phone.

The exovent chamber consists of a base fitted onto a standard hospital bed that contains its own section of mattress and a removable top that fits over the torso with neck and hip seals (see link to pics below). A free-standing pump unit is connected to the base by flexible hoses and a control unit allows adjustment of pressure around the torso. The subject's torso can be observed through a window and accessed through portholes that seal around the healthcare provider's arms. The thin neoprene neck and hip seals are fitted loosely onto the person before the chamber being put in place, and then adjusted.

Testing was performed on six healthy adult volunteer members of the development team in the presence of three senior anaesthetists. All of the subjects were tested in the supine position (facing up) and slightly tilted up, while three were also tested in the prone (facing down) position. Various negative pressure settings were tested and spirometry (lung performance) readings recorded. These showed that the exovent was able to deliver both an increased lung expansion to people breathing spontaneously, and powerful ventilation to take over people's breathing entirely, using only moderate negative pressures.

Nurses reported that the exovent chamber could be positioned and removed quickly by two people. They noted that the window and portholes would allow them to monitor and look after their patients safely, despite the inevitably reduced direct access to their torsos. When supine, the subjects' heads could be positioned easily to allow view of the larynx for tracheal intubation, should that become necessary, without needing to remove or adjust the neck seal. For patients that progress to needing intubation, it would probably not be necessary to keep them in the exovent (though it would be easy and safe to do so) - and in the event of an emergency intubation, there would be no need to delay while the exovent was removed.

The volunteers all found the chamber comfortable, and in particular reported that the neck and hip seals were soft and easy to adjust, and that they could voluntarily breach them to stretch their arms or touch their faces without this significantly affecting the stability of the chamber pressure.

Importantly, all the test subjects felt 'in control' knowing that they could immediately release the vacuum by opening a wide gap under one of the seals if they wished. When the ventilation mode was used, the subjects all allowed the exovent to take over their breathing without feeling any desire to 'fight it' or that it felt unnatural or uncomfortable, and described the sensation as relaxing; one participant fell asleep within minutes.

"We are really excited to be unveiling this life-saving system which is a cutting-edge reinvention of pre-existing technology," says exovent CEO and article co-author Ian Joesbury. "As the patient does not need to be sedated it opens up alternative treatment options that may allow more patients with COVID-19 to be treated outside of intensive care."

It is estimated that the UK version of the exovent will cost approximately £8000 GBP (US $10,496, €8856), which is considerably cheaper than existing positive-pressure devices, which cost around £15,000 GBP for CPAP and over £30,000 GBP for intensive care ventilators. It is also estimated that a lower-cost global version of the exovent could be produced for less than £500 (US$652, €550).

The authors add: "Anticipated advantages of the exovent over positive-pressure ventilators, which may be especially relevant in low- and middle-income countries, include the lower resources required to ventilate conscious patients, and the potential for greater oxygen conservation, since oxygen would only need to be supplied to the patients directly via a facemask or nasal prongs when required, rather than the continuous oxygen supply needed for positive pressure systems."

They explain that because it is so much less invasive and so much easier to do than PPV, the threshold for using exovent when available will be much lower, and many more patients will be eligible for therapy. Even if hospitals in low- and middle-income countries have conventional intensive care ventilator hardware available, the resources required to (a) intubate, paralyse and sedate them as is necessary, and (b) to manage them whilst unconscious which means intensive nursing, intravenous nutrition or tube nutrition, skin care, etc, are too scarce to make intensive care ventilation available to any but a very few individuals. The authors explain: "It is about staffing more than equipment, and the exovent would be much easier and less expensive to use."

Thanks to the investment of over £1m of volunteer time from the exovent team, rapid development and prototyping by Marshall ADG, and partnership with Warwick Manufacturing Group (WMG) High Value Manufacturing Catapult, the system is now ready for a formal assessment and approval. The authors plan to submit the design to the Medicines and Healthcare products Regulatory Agency (MHRA) which regulates medical devices in the UK, and hope to receive approval by the middle of 2021.

Credit: 
AAGBI

Mental health conditions alarmingly high among children with autism

Nearly 78 per cent of children with autism have at least one mental health condition and nearly half have two mental health conditions or more, according to a new U.S. study from the University of British Columbia's department of psychology and the AJ Drexel Autism Institute at Drexel University (Pennsylvania).

The study also found mental health conditions present in 44.8 per cent of pre-school age children with autism. The scope of the issue among that age group had not previously been established using a large, population-based sample.

By contrast, the study found that only 14.1 per cent of youth without autism (ages 3-17) had mental health conditions.

It is the first research since 2008 to examine the prevalence of mental health conditions among children with autism at a population level, and signals a need for healthcare systems to adapt to account for the overlap.

"For a long time, mental health in kids with autism was neglected because the focus was on autism. There's much greater awareness now, but we don't have enough people trained to provide mental health treatments to kids on the autism spectrum," said Dr. Connor Kerns, an assistant professor in UBC's psychology department and lead author of the study. "We need to bridge these two systems and the different sets of providers that tend to treat these children."

Autism, or autism spectrum disorder (ASD), is a complex brain development disorder that impacts approximately 2.6 per cent of the U.S. population. People with autism can have difficulty communicating and interacting socially. They often demonstrate restricted, repetitive behaviour patterns. The term "spectrum" reflects the fact that symptoms can vary widely from one person to the next.

The researchers analyzed data from the 2016 National Survey of Children's Health, a survey of more than 42,000 caregivers with a total of 1,131 ASD-diagnosed children in their care.

These children were considered to also have a mental health condition if the parent/caregiver had reported a healthcare provider diagnosing the child with any of the following:

anxiety (39.5%)

depression (15.7%)

behavior/conduct problem (60.8%)

Tourette syndrome (1.8%)

ADHD (48.4%)

Mental health conditions became more prevalent as children with autism grew older. Still, the 44.8-per-cent prevalence among pre-school children is significant because early intervention is known to increase the effectiveness of mental health treatment.

The study compared the prevalence of mental health conditions in children with ASD, children with intellectual disabilities, and children with other ongoing, chronic conditions that require attention from the healthcare system. Mental health conditions were significantly more prevalent among children with autism than among the other groups.

For example, anxiety was 6.3 times more prevalent among children with autism than among children with intellectual disabilities, and three times more prevalent than it was among children with other special healthcare needs.

"There's something specific about autism that is increasing this mental health burden, and it's true not only for anxiety, but also for depression, behaviour problems and attention problems. This is a special population that requires special attention," said Dr. Kerns.

The researchers hope these eye-opening new numbers will prompt changes to public policy that make it easier for mental health treatments to be approved and funded for children with autism.

"If we think about ways to screen and intervene against these mental health conditions before these children even get to school, then we might be way ahead of the game," said Dr. Kerns. "The longer mental health conditions are allowed to exist and worsen, the harder they are going to be to treat. It's much better to catch them early. Right now, we don't have a great system for doing that."

Credit: 
University of British Columbia

ALS study reveals a unique population

image: Maltese out on a Sunday, on one of the busiest streets in Valletta, Malta's capital city

Image: 
Source: Jonathan Borg, Times of Malta

Malta, a sovereign microstate in the middle of the Mediterranean Sea, has no shortage of sunny beaches, honey-bricked villages and rugged countryside. Beyond its Mediterranean charm, Malta is home to a geographically and culturally isolated population whose unique genetic makeup, makes this island nation a goldmine for genetics research.

Four years ago, the University of Malta set up a national ALS Registry and Biobank to identify patients with amyotrophic lateral sclerosis (ALS) and collect data on their residence, occupation, lifestyle and environmental exposures. Blood samples donated by participants will remain stored in high-tech storage facilities at the University over many years.

ALS is a progressive neurological disease that destroys the nerves that interact with the body's muscles. The disease typically leads to complete paralysis of the body, robbing patients of their ability to walk, speak, eat and breathe. There is no cure for ALS, and eventually, the disease is fatal.

Malta's ALS Biobank is providing scientists with an invaluable resource for understanding the causes of ALS. In the first landmark study, researchers have retrieved and scrutinised the DNA from blood samples to discover flaws in genes linked to ALS.

"The DNA results caught us by surprise. The most frequently mutated ALS genes were flawless in Maltese patients," said the study's lead researcher Dr Ruben J. Cauchi, PhD, a senior lecturer at the University's School of Medicine and lead investigator at the University's Centre for Molecular Medicine and Biobanking.

Collaborating with scientists at the University Medical Centre (UMC) Utrecht in The Netherlands, University of Malta researchers found that ALS patients in Malta did not have flaws in the C9orf72, SOD1, TARDBP and FUS genes, which are known to contribute to a major number of ALS cases worldwide.

The study nonetheless revealed that compared to other European populations, a higher percentage of Maltese patients with no prior family history of ALS have harmful flaws in their DNA. Intriguingly, these occur in genes that are rarely damaged in Europeans with ALS.

"Our results underscore the unique genetics of the Maltese population, shaped by centuries of relative isolation. We also established that genetic factors play a significant role in causing ALS in Malta," added Dr Cauchi.

Right now, the research team is on the hunt for what triggers ALS in more than half of the study subjects that had no flaws in known ALS genes. Thanks to the participation of patients and healthy volunteers, Malta's ALS Biobank is rapidly growing into a precious treasure trove of data that is expected to unveil more fascinating insights on the causes of ALS in the years to come.

Credit: 
University of Malta